Search
KALA BIO Inc
KALAAdd to Watchlist
0.781USD
+0.051+7.04%
Close 07-31 16:00（ET）Quotes delayed by 15 min
290.41KMarket Cap
LossP/E TTM
More Details of KALA BIO Inc Company
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
KALA BIO Inc Info
Ticker SymbolKALA
Company nameKALA BIO Inc
IPO dateJul 20, 2017
CEOLazar (David Elliot)
Number of employees38
Security typeOrdinary Share
Fiscal year-endJul 20
Address1167 Massachusetts Avenue
CityARLINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02476
Phone17819965252
Websitehttps://www.kalarx.com/
Ticker SymbolKALA
IPO dateJul 20, 2017
CEOLazar (David Elliot)
Company Executives of KALA BIO Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Elliot Lazar
Mr. David Elliot Lazar
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
240.00K
--
Mr. Darius Kharabi
Mr. Darius Kharabi
Chief Business Officer
Chief Business Officer
717.00
-58.02%
Dr. Kim Brazzell, Ph.D.
Dr. Kim Brazzell, Ph.D.
Head of Research and Development, Chief Medical Officer
Head of Research and Development, Chief Medical Officer
--
--
Mr. Howard B. (Howie) Rosen
Mr. Howard B. (Howie) Rosen
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Director
Director
--
--
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Lead Independent Director
Lead Independent Director
--
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Director
Director
--
--
Mr. C. Daniel Myers
Mr. C. Daniel Myers
Independent Director
Independent Director
--
--
Dr. Marjan Farid, M.D.
Dr. Marjan Farid, M.D.
Independent Director
Independent Director
--
--
Ms. Taylor Steiner
Ms. Taylor Steiner
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David Elliot Lazar
Mr. David Elliot Lazar
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
240.00K
--
Mr. Darius Kharabi
Mr. Darius Kharabi
Chief Business Officer
Chief Business Officer
717.00
-58.02%
Dr. Kim Brazzell, Ph.D.
Dr. Kim Brazzell, Ph.D.
Head of Research and Development, Chief Medical Officer
Head of Research and Development, Chief Medical Officer
--
--
Mr. Howard B. (Howie) Rosen
Mr. Howard B. (Howie) Rosen
Independent Director
Independent Director
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Director
Director
--
--
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Lead Independent Director
Lead Independent Director
--
--
FAQs
Who are the top five shareholders of KALA BIO Inc?
The top five shareholders of KALA BIO Inc are: Mr. David Elliot Lazar
How many institutions hold shares of KALA BIO Inc (KALA)?
As of 2026Q1, 77 institutions hold shares of KALA BIO Inc, with a combined market value of approximately 7.26M, accounting for 0.78% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4611334.00.